<DOC>
	<DOCNO>NCT00189982</DOCNO>
	<brief_summary>The purpose study evaluate whether rAHF-PFM safe effective treatment child hemophilia A . The study open pediatric patient Canada complete Baxter Study 060101 .</brief_summary>
	<brief_title>Efficacy Safety Study Recombinant Protein-Free Factor VIII ( rAHF-PFM ) Pediatric Patients Canada With Hemophilia A - A Continuation Baxter Study 060101</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subject must participate complete participation Baxter 's clinical study 060101 Subject parent/legally authorize representative provide write informed consent Subjects withdraw Baxter 's Clinical Study 060101 prior termination study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>